about us

Home page

CHENGDU SHENGNUO BIOPHARMACEUTICAL

Chengdu Shengnuo Biopharm Co., Ltd. (hereinafter referred to as “Shengnuo Biopharm”) is a wholly-owned subsidiary of Chengdu Shengnuo Biotechnology Co., Ltd. It was established in October, 2004 and is regarded as a "High-tech Enterprise Certified by Sichuan Province" and a "Sichuan Provincial Enterprise Technology Center". With a registered capital of 50 million yuan, it possesses over 50 key technologies for the large-scale production of peptides that have been marketed both domestically and internationally. It is a mature professional enterprise in China for the large-scale production of peptides and amino acid drugs, with a single batch output reaching the kilogram level and has passed the US FDA certification.

Chengdu Shengnuo Biopharm Co., Ltd. is a specialized, sophisticated, and innovative enterprise and a national high-tech enterprise specializing in the peptide field, which went public in 2021. We integrate R&D, production, and sales, with business covering peptide active pharmaceutical ingredients (APIs), cosmetic bioactive peptides, CDMO services, and peptide formulations. As a leading company in China's peptide API sector, we focus on the development, production, and technical services of peptide drugs, possessing full industrial chain capabilities from drug discovery to commercial manufacturing.

2004

Company incorporation

5000 +

Capital of 50 million yuan

50 +

More than 50 key technologies

2000 +

Global partners

Peptide R&D Center

The center has been deeply involved in the field of peptides for more than 20 years, and has peptide API process research laboratories with a total area of 3,000 square meters, peptide API pilot plants with a total area of 1,500 square meters, GMP grade workshops for peptide API and topical drug development with a total area of 3,000 square meters, and drug development and analysis laboratories with a total area of 5,200 square meters. It has a professional R&D team of over 400 staff, and has successively carried out more than ten national and provincial scientific research projects, such as the National Major Special Project for Innovative Drug, covering multiple treatment areas including digestive system, immunity, tumor, hepatitis B, diabetes and obstetrics, and has obtained approval of more than 20 drugs, and plays an important role in promoting the development of China's peptide drug research and industrialization.

Four major production bases

Shengnuo Biotech Production Base

Area ofland occupied: 110 mu Headquarter Building R&D Center Freeze-dried powder for injection/Injection solution (Non-terminal sterilization) with a capacity of 10 million bottlesor 75 million bottles per year. Freeze-dried powder for injection/njection solution (Non-terminal sterilization/high activity) with a capacity of 10million bottles or 60 million bottles per year. Pre-filled syringes/Cartridges injection with a capacity of50 million vials or 15 million vialsper year. Penicillin injection (Terminal sterilization) with a capacityof55 million bottles per year.

Shengnuo Biopharm Production Base

Area of land occupied: 103 mu APIs with a capacity of 1,000 kg per year (14production lines in total). Solid oral drugs: 100 million tablets per year.Freeze-dried powder for injection with a capacity of10 million bottles per year. Penicillin injection with a capacity of 10 million bottles per year. Pre-filled syringe with a capacity of5 million vialsper year. Cartridge injection with a capacity of 5 million vialsper year.

Meishan Huilong Production Base

Area ofland occupied: 75 mu APIs with a capacity of 2.000 kg per year (8 production lines in total)

Kaijie Peptide Production Base

Area ofland occupied: 65 mu. CDMO production line with a capacity of 100 kg peryear (20 production lines in total). Cosmetic peptide solution with a capacity of 4.000tons per year.

Expert team

Expert Group for the Practice of Peptide Pharmacy Research

Innovative Drug and Generic Drug Development

Synthesis and Modification of Highly Complex Peptides

Purification of Complex Peptides

Synthetic Process Research and Optimization

Mass Production and Quality Control

Drug Application and Registration

An average of 15+ years of research and practical experience in peptide synthesis

Sichuan Province's top talent introduction of leading innovative and entrepreneurial teams

Provide CDMO services for more than 50 innovative drugs, several of which have been approved and marketed, and more than 30 of which are in clinical trials.

Lead 5 "Eleventh Five-Year" National Major Special Project for Innovative Drug: Atosiban Acetate, Octreotide Acetate, Somatostatin, Thymalfasin (thymosin alpha 1) and Carbetocin. All of them achieved commercially produce.

Completion of two domestic First Approved Generic Drugs: Enfuvirtide for injection and Carbetocin injection.

Complete the synthesis and mass production of several highly complex peptide drugs such as Liraglutide, Semaglutide, Tirzepatide and Enfuvirtide.

Yongjun Wen

Master of Chemistry from Lanzhou University, Founder and President of ShengnuoBiotec. He Led the development of China's frst three NMPA-approved peptide drugs“Thymopentin, Thymalfasin, Somatostatin), and awarded the "Outstanding Contributionto Peptide Applications" at the 10th and 12th International Peptide Symposia, andhonoredas a "Chengdu Outstanding Expert with Eminent Contributions."

Xiaoyu Hu

Professor at Lanzhou University, Former student of Nobel Laureate Professor RogerGuillemin, Chairman of the Chinese Peptide Symposium, Committee Member of thePeptide Drug Committee and Chinese Pharmaceutical Association. He conductedextensive research on bioactive peptides with signifcant biological activities. and wasrecognized for notable achievements and prominence in the feld of peptide research.

CORPORATE CULTURE

mission

Devoting to the peptide industry, safeguarding life and health.

vision

Innovation leads development, becoming the leader in the peptide industry.

core values

Customer first, win-win cooperation. People-oriented, co-creation and sharing.

Development History

2001

2001, the company was founded.and started to carry out CDMO services and the development of its own products.

2006

2006, the company moved to Dayi and participated in the "Eleventh Five-Year"National Major Special Project for Innovative Drug.

2007

2007,the company got its first GMP certificate and its first drug registration license of thymopentin for injection.

2012

2012, the company got its first US FDA Type II DMF registration for Bivalirudin API.

2015

2015, the company got its US FDA Type Il DMF registration for Liraglutide API.

2016

2016,the company got the First Approved Generic Drug for Carbetocin injection in China.

2018

2018, an innovative drug of its first CDMO service customer got market authorization in China.and Bivalirudin preparation of a CDMO service customer got market authorization in US.

2021

2021,Eptifbatide injection passed the National Quality and Efficacy Consistent Evaluation of Generic Drugs and got approval from China authority, the company completed IPO and was listed and traded on the Kechuan Board of Shanghai Stock Exchange.

2022

2022,acetate atosiban injection and carbetocin injection passed the National Quality and Efficacy Consistent Evaluation of Generic Drugs and got approval from China authority.The company has entered the cosmetic peptide industry by applying the cutting-edge technology of peptide medicine to the research and development of cosmetic peptide APIs.

International first-class production environment and equipment